Edibles sales in the Canadian market will not start until 2020, at least according to an executive at a marijuana-producing company.


During the Lift & Co. (TSXV:LIFT,OTCQB:LFCOF) Cannabis Business Conference (LCBC), the Investing News Network had the chance to catch up with Peter Aceto, CEO of CannTrust Holdings (NYSE:CTST,TSX:TRST), to talk about the company’s path and the upcoming edibles market in Canada.

Aceto explained that the current barrier to entry for many consumers looking into cannabis products is the smokeable aspect of the current legal offerings in Canada.

“My guess is probably the first Canadian will not purchase their first edible product legally in 2019,” Aceto said.

Aceto participated in a panel at the LCBC during which Vivien Azer, managing director for consumer research in the beverages, cannabis and tobacco markets for Cowen (NASDAQ:COWN), predicted that edibles will not be available for sale in 2019.

“We will have some new form factors as soon as they’re legal and lawful and we’re working on a variety of other verticals as well,” Aceto said.

CannTrust reached the New York Stock Exchange (NYSE) in February. Aceto said this premier listing has allowed the company to meet with institutional investors who previously did not have access to the company’s shares.

“They see a much bigger valuation opportunity in the US, so I think Canadian capital is looking that way,” Aceto said.

However, he added that institutions and global investors who are just now entering the marijuana market have a big impetus for the established market of companies with senior US listings.

While Aceto spoke during a panel at the event, he was also there to announce the firm’s new social investment campaign, dubbed the We Care program. For it, CannTrust will partner with the Canadian Alliance to End Homelessness, Project SHARE and Hospice Niagara.

The company explained that this is part of a platform aimed at helping local causes and said that it will be based on four identities: lifting people out of poverty, health and wellness, safe consumption and sustainability.

“I’ve always wanted to work with companies that balance all of their stakeholders. Yes, we have to make money and that is very, very important, that’s why we’re here. But we have to help our employees, we have to be good citizens in the community that we live (in) and where we work,” Aceto said.

In total, as part of the first group of social causes, the company will donate C$75,000 this year, with a planned C$25,000 annually for the next three years for the Hospice Niagara organization.

For more on what Aceto had to say, watch the interview above. You can also click here to see our full Lift & Co. Cannabis Expo playlist on YouTube.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less